In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 3, 2008, Pages

  Liu, Jien Wei ^a   Wang, Lih Shinn ^b   Cheng, Yu Jen ^c   Hsu, Gwo Jong ^d   Lu, Po Liang ^e   Liu, Yung Ching ^f   Chen, Chih Ming ^g   Lee, Chun Ming ^h   Sun, Wu ⁱ   Jang, Tsrang Neng ^j   Chiang, Ping Cherng ^k   Chuang, Yin Ching ^l   Lin, Hsiu Chen ^m   Shi, Zhi Yuan ⁿ   Kung, Hsiang Chi ^o   Huang, Cheng Hua ^p   Tsao, Shih Ming ^q   Lu, Chin Te ^r   Liao, Chun Hsing ^s   Hsueh, Po Ren ^o  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^h MACKAY MEMORIAL HOSPITAL   (Taiwan)

ⁱ Pao Chien Hospital   (Taiwan)

^j SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l CHI MEI MEDICAL CENTER   (Taiwan)

^m TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁿ TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^o NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^p CATHAY GENERAL HOSPITAL   (Taiwan)

^q CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^r LOTUNG POH AI HOSPITAL   (Taiwan)

^s FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

Acinetobacter baumannii; Antibacterial drug resistance; Taiwan; Tigecycline

Indexed keywords

AMIKACIN; CIPROFLOXACIN; IMIPENEM; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EXPOSURE; HOSPITAL; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TAIWAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TAIWAN;

EID: 55649117054     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70026-8     Document Type: Article

References (31)

1. Schreckenberger P.C., and von Graevenitz A. Acinetobacter, Achromobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative Gram-negative rods. In: Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., and Yolken R.H. (Eds). Manual of Clinical Microbiology. 7th ed. (1997), ASM Press, Washington, DC 539-560
2. Joly-Guillou M.-L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 11 (2005) 868-873
3. Falagas M.E., and Karveli E.A. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 13 (2007) 117-119
4. Falagas M.E., Bliziotis I.A., and Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 10 (2006) R48
5. Falagas M.E., and Rafailidis P.I. Attributable mortality of Acinetobacter baumannii : no longer a controversial issue. Crit Care 11 (2007) 134
6. Falagas M.E., Kasiakou S.K., Rafailidis P.I., Zouglakis G., and Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 57 (2006) 1251-1254
7. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62 (2008) 45-55
8. Rice L.B. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2 (2006) S100-S105
9. American Thoracic Society, and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
10. Clinical and Laboratory Standard Institute. Performance standards for an- timicrobial susceptibility testing: M100-S16; 16th informational supplement (2006), Clinical and Laboratory Standard Institute, Wayne, PA
11. Song J.Y., Kee S.Y., Hwang I.S., Seo Y.B., Jeong H.W., Kim W.J., et al. In vitro ac- tivities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60 (2007) 317-322
12. Seifert H., Stefanik D., and Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 58 (2006) 1099-1100
13. Pachón-Ibáñez M.E., Jiménez-Mejías M.E., Pichardo C., Llanos A.C., and Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48 (2004) 4479-4481
14. Draghi D.C., Tench S., Dowzicky M.J., and Sahm D.F. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 54 (2008) 91-100
15. Mezzatesta M.L., Trovato G., Gona F., Nicolosi V.M., Nicolosi D., Carattoli A., et al. In vitro activity of tigecycline and comparators against carbapenem- susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob 7 (2008) 4
16. Scheetz M.H., Qi C., Warren J.R., Postelnick M.J., Zembower T., Obias A., et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007) 1621-1626
17. Struelens M.J., Carlier E., Maes N., Serruys E., Quint W.G.V., and van Belkum A. Nosocomial colonization and infection with multi-resistant Acinetobacter baumannii : outbreak delineation using DNA macrorestriction and PCR fingerprinting. J Hosp Infect 25 (1993) 15-32
18. Hsueh P.R., Teng L.J., Chen C.Y., Chen W.H., Yu C.J., Ho S.W., et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 8 (2002) 827-832
19. Maniatis A.N., Pournaras S., Orkopoulou S., Tassios P.T., Lagkis N.J., and the Bacterial Resistance Study Group. Multiresistant Acinetobacter baumannii isolates in intensive care units in Greece. Clin Microbiol Infect 9 (2003) 547-553
20. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., et al. Citywide clonal spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 162 (2002) 1515-1520
21. Tacone F.S., Rodriguez-Villalobos H., de Backer D., de Moor V., Deviere J., Vincent J.L., et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25 (2006) 257-260
22. Leclerc T., Perez J.P., Debien B., Clapson P., and Lenoir B. Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination [in French]. Ann Fr Anesth Reanim 26 (2007) 1056-1058
23. Wadi J.A., and Al Rub M.A. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 27 (2007) 456-458
24. Curcio D., Fernandez F., and Duret F. Tigecycline use in critically ill older patients: case reports and critical analysis. J Am Geriatr Soc 55 (2007) 312-313
25. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., and Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27 (2007) 1198-1201
26. Schafer J.J., and Mangino J.E. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 14 (2008) 512-514
27. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., and Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug- resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 46 (2008) 567-570
28. Schafer J.J., Goff D.A., Stevenson K.B., and Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug resistant Acinetobacter baumannii. Pharmacotherapy 27 (2007) 980-987
29. Garrison M.W., Neumiller J.J., and Setter S.M. Tigecycline: An investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther 27 (2005) 12-22
30. 2+ cleavage of 16S rRNA. J Antimicrob Chemother 53 (2004) 592-599
31. Chopra I., and Robert M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 (2001) 232-260